All Rights reserved
Newly updated treatment guidelines issued by the Department of Health and Human Services support the use of the fusion inhibitor Fuzeon with an active boosted protease inhibitor in patients with three-class virologic failure, as this treatment approach results in better and more prolonged virologic suppression than other regimens. The evidence cited in the treatment guidelines update includes several recent clinical trials of new boosted protease inhibitors in treatment-experienced patients, which demonstrated a better and more prolonged virologic response when used in conjunction with Fuzeon.
The guidelines, titled "Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents," provide clinicians and other health care providers direction for using antiretroviral drugs to treat HIV-positive adults and adolescents. Fuzeon, the only fusion inhibitor available for the treatment of HIV, was codeveloped by Roche and Trimeris. (Advocate.com)